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ABSTRACT 
Transdermal drug delivery is involved in the transportation of drug through the skin for systemic circulation. Now a day’s more than 74% of 
drugs are administered drug in the form of tablet, capsule, which are taken orally but sometimes those are not effective as desired due to 
physiological activities of body. The major obstruction caused by stratum corneum to penetrate the drug. So there is need to facilitate the 
stratum corneum to increase the flux, a number of approaches are used to enhance the penetration of drug. Transdermal drug delivery system 
(TDDS) are very effectively overcome the hepatic first pass metabolism and improve the steady plasma drug concentration. The present review 
article provides an overview of various types of transedrmal patches, method of preparation and their evaluation. 
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Introduction- 
Transdermal drug delivery is one of the most approachable 
controlled drug delivery system by which we can topically 
administered medicament in the form of patches by which 
drugs are delivered for systemic circulation with a controlled 
rate. The TDDS offers many advantages upon conventional 
dosage form including more patient compliance, elimination 
of hepatic first pass metabolism, more uniform plasma level, 
prolong action to reduce the dosing frequency. 
Advantages of transdermal drug delivery 
system(1,2): 
1- Ease of handling, self-administration is possible. 
2- Avoid the first pass metabolism of drug. 
3- In case of any adverse action, it can be easily 
discontinued by simply detaching the patches. 
4- Avoid the interaction of drug with gastro-intestinal 
fluid and other medication, thus improve the bio-
availability. 
5- A predetermined and stable drug plasma concentration 
of drug can be achieved. 
6- It is easy to applicable in nauseated or unconscious 
patient. 
7- The patches can be designed for prolong action. It may 
ranges from few hours to weeks. 
Disadvantages of transdermal drug delivery 
system(3): 
1- Sometime drug or excipient may cause the skin 
irritation. 
2- Drugs with hydrophilic characteristic are slowly 
permeate through stratum corneum. 
3- Due to variable thickness of skin from one place to 
another or with age, the permeability of drug is 
affected. 
4- It is costlier than conventional dosage form. 
5- Higher molecular weight of drug (>500Da) is usually 
difficult to cross the stratum corneum.  
Component of transdermal drug delivery system: 
(1) Polymer Matrix(4,5,6,7):- Polymers are the base of TDDS 
that manage the release of drug from the devices. The 
drug and other excipient are embedded in Polymer 
matrices and that can be prepared by dispersion. Hence 
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the polymer should be stable, nontoxic, inexpensive, 
compatible with wide variety of drug molecule and 
excipients, that are easily facilitate the diffusion of drug 
from the matrices with desired rate and also capable of 
consist large amount of drug material.  
Types of polymer-: 
Natural polymer:- Zein, shellac, gelatin, cellulose 
derivatives, chitosan, gum, natural rubber etc. 
Synthetic elastomer:- Poly-butadiene, nitrile, acrylonitrile, 
silicon rubber, neoprene, butyl rubber, etc. 
Synthetic polymer:- Hodroxy propyl methyl cellulose, 
polyvinyl pyrrolidine, polyvinyl chloride, polyvinyl acetate, 
polyacrylate, poly propylene, poly urea, poly methyl metha 
acrylate, ethyl cellulose, eudragit etc. 
(2) Drug(8,9):- The suitable choice of drug is based on the 
phisico- chemical and pharmaco-kinetic properties. 
Which are basically daily dose of drug should be less 
than 5 mg/day, molecular weight should be less than 
500 dalton, log P value varying from 1-3, drug should 
have short biological half lives, extensive first pass 
metabolism.. 
(3) Permeation enhancer(10,11):- Permeation enhancer 
promotes the transportation of the drug from the patch 
to the skin. Permeation enhancers are act by altering 
the barrier properties of skin by improved fluidity of 
membrane structure or by facilitation of drug solubility 
within the skin. These permeation enhancer are 
characterized as chemical and physical method of 
enhancement.  
(a)- Chemical enhancer:- Sulfoxide like DMSO, alcohols, 
polyols like propylene glycol, fatty acid like oleic acid, esters 
like ethyl acetate, amines like urea, terpenes both mono and 
di sesquiterpenes and surface active agents – both anionic 
like SLS and cationic like pluronic F 127. 
(b- Physical Enhancer(12):-Physical enhancement is based 
on electrical techniques like electroporation, phonophoresis, 
iontophoresis etc. and velocity based devices like liquid jet 
injection. 
(4) Other Excipients(13,14):- 
(a): Adhesive:- The pressure sensitive adhesive helps in 
fastening of the device to the skin which is positioned on the 
face or back of the device. It should possess the following 
characteristics- 
 It should aggressively stick to the skin surface. 
 It should easily peel off and dosen,t leave any leftover 
on the skin. 
 It should be physically and chemically compatible with 
drug and excipients. 
 It should not cause sensitization to the skin. 
 In case of face adhesive system the drug permeation 
should not affected. 
(b): Backing Laminate(15,16): The backing laminate protect 
the patch from outer environment. It should have the low 
water transmission rate to facilitate the hydration of skin by 
which increase the solubility and permeation of medication. 
Backing laminate also should be compatible with drug and 
other excepients and having a great rigidity. For example 
poly vinyl acetate, poly propylene, cellulose derivatives etc. 
(c): Release liner(17): release liners are responsible to 
protect the patch during storage. It should be removed 
before the application of patch. Because of the liner is in 
contact to the patch it should comply the chemical inertness. 
Types of formulation of TDDS: 
(A): Adhesive dispersion type system(18): Such a system 
polymer reservoir is fabricated by dispersing drug in 
adhesive polymer, which is then pour on flat sheet of drug 
impermeable metallic plastic backing membrane through 
solvent casting or hot melting to obtain drug reservoir. The 
drug reservoir layer is then covered by a non-medicated rate 
controlling adhesive polymer membrane to produce an 
adhesive diffusion controlled drug delivery system.
 
 
Fig-1. Adhesive diffusion controlled transdermal drug delivery system 
 
(B): Membrane permeation controlled system(18,19,20): In 
this the drug is  homogeneously dispersed in solid polymer 
matrix to fabricate the reservoir, it is the either dissolved in a 
releasable solvent to form a gel like or suspended in a 
unleachable viscous liquid medium to form a gel like 
suspension and then completely enclosed  in a compartment 
molded between a drug impermeable metallic plastic 
backing laminate and a rate controlling polymeric 
membrane. 
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Fig-2.  Membrane moderated transderml drug delivery system 
 
(C): Matrix diffusion controlled system(8,14): The drug is 
diffused homogeneously in a hydrophilic polymer matrix. 
This drug embedded polymer matrix is then fixed on an 
occlusive base plate in a compartment fabricated from a 
drug impermeable plastic backing laminate. The adhesive is 
spread along the circumference of drug reservoir to form a 
adhesive rim. 
 
 
Fig-3. Matrix diffusion controlled transdermal drug delivery system 
(D): Microreservoir type controlled system(4,18,21,22): This 
kind of TDDS is a combination of reservoir and matrix 
dispersion system. The drug reservoir is prepared by first 
suspending the drug in solution of water soluble polymer 
and then dispersing the formed drug suspension in a 
hydrophobic polymer homogeneously to form thousands of 
unleachable microscopic spheres of drug reservoir.These 
formulated dispersion are thermodynamically unstable and 
stabilized by crosslinking of polymer. 
 
 
Fig- 4. Microreservoir controlled Transdermal drug delivery system 
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Various methods of preparation of TDDS- 
(A): Circular Teflon mould method(19,22,23,24,25)- In this 
method blend of polymers in various ratio are used in 
organic solvent. This polymer solution is divided in two 
equal halves, in one half of polymer solution the calculated 
amount of drug is dissolved and enhancer is added in 
another half of polymer solution. Now these two halves are 
mixed in one another and plasticizers is added to this and 
stir for 12 hours and then poured in to a circular Teflon 
moulds. These moulds are placed on a horizontal plane 
surface and covered with inverted funnel to limit the 
evaporation of solvent in a laminar flow hood for 24 hours 
with an air speed 0.5 m/s. The dried films are to be stored in 
a desiccators containing silica gel for another 24 hours at 25 
±0.50C. 
(B): Mercury substrate method(19,22,26): In this method 
took the drug along with plasticizer and dissolved in polymer 
solution. The solution is to be stirred for 10 - 15 minutes to 
produce a homogeneous dispersion and discharged in to a 
horizontal plane mercury surface and covered with an 
inverted funnel to limit the solvent evaporation. 
(C): By using EVAC membrane method(27,28): In order to 
prepare the target transdermal therapeutic system, 1% 
carbopol is used to form the reservoir gel and polyethylene, 
ethylene vinyl acetate  copolymer membrane can be used as 
rate controlling membrane. Propylene glycol may be used for 
insoluble drug to prepare the gel. Drug is dissolved in 
propylene glycol, carbonyl resin is added to the above 
solution and neutralized by using 5% w/w sodium hydroxide 
solution. The medicated gel is poured on a sheet of backing 
layer occupying the specified area. The rate controlling 
membrane is placed on medicated gel and the edges will be 
sealed to prevent escaping of the gel by heat to obtain a leak 
proof device. 
(D): By using IPM membrane method(29,30): In this method 
a mixture of water and propylene glycol containing carbomer 
940 polymer is prepared and the drug is dispersed in it  and 
stirred for 12 hours on magnetic stirrer. The dispersion is 
neutralized and made viscous by addition of triethanolamine. 
The formed gel will be incorporated in the IPM (isopropyl 
myrstitate membrane). 
(E): Aluminium backed adhesive film method(28,31): When 
the loading dose of drug is more than 10mg the transdermal 
drug delivery system may produce unstable matrices, then 
drug is dissolved in chloroform and adhesive material will be 
added to the drug solution and dissolved. A custammade 
aluminium film former is lined with aluminium foil and the 
ends blanked off with tightly fitting cork blocks. 
(F): Prepartion of TDDS by using proliposomes(28,32,33): 
Proliposomes are prepared by adding 5 mg mannitol in 
100ml round bottom flask which is kept at 60-700c temp and 
flask is rotated at 80-90 rpm and dried in vaccum for 30 
minutes. After drying the temp of water bath is adjust to 20-
300C. Drug and lecithin in ratio of (0.1:2.0) dissolved in 
suitable organic solvent. A 0.5ml aliquot of organic solution 
is added to rbf at 370C and second aliquot (0.5 ml) of organic 
solution is added after complete drying. After the last 
loading, the flask connected to the lyophilizer. The prepared 
proliposomes placed in dessicator for overnight and passed 
through 100 mesh sieve and stored in glass bottle at freeze 
temperature. 
Evaluation of transdermal patch: 
(1) Thickness of patch(23,34,35,36): The thickness of patch is 
measured at different places with the help of digital 
micrometer or screwgauze and determine the average 
thickness of the film. 
(2) Weight uniformity test(34,35,36): For the weight 
variation patches are selected randomly and dried at 
600C for 4 hours. Each patches are weighed individually 
and calculate the average weight. The individual weight 
should not deviate from average weight.  
(3) Moisture content test(35,36,37,38): The prepared 
patches are weighed individually and place in a 
desiccators containing calcium chloride at room 
temperature for 24 hours or activated silica for 12 
hours. The patches are weighed again after a specified 
period of time till the patches does not show a constant 
weight. It is  measured by the formula: 
                  
                           
             
     
(4) Folding endurance (34,35,36,39): The prepared patch is 
folded at a place repeatedly till it has broken. The 
numbers of times folded at the same place without 
breaking gives the value of folding endurance. 
(5)  Drug Content Uniformity (28,40): The specified area of 
patch is dissolved in suitable solvent and shaken 
continuously for 24 hours. Then the solution is filtered 
through filter media and after making a suitable 
dilution the solution is estimated 
spectrophotometrically. 
(6) Water absorption test(35,36,40): Weighed films were 
kept in a desiccators at room temperature for 24 hours. 
These were then exposed to saturated solution of 
Potassium chloride in order to maintain 84% relative 
humidity until a constant weight is attained. The 
percentage moisture uptake is calculated by formula: 
                 
                          
               
     
(7) Shear adhesion test(22,34,36): The shear strength of an 
adhesive polymer is depend on cohesive property of 
polymer, Which can be influenced by molecular weight, 
composition of polymer, degree of cross linking and the 
type of amount of tackifier added. In this an adhesive 
coated tape is applied on to stainless steel plate, a 
specified weighed is hung from the plate. Shear 
adhesion strength is determined by measuring the time 
it takes to pull off the tape from the plate. More the 
time taken, greater the shear strength. 
(8) Peel adhesion test(22,34,36): Force required to detach 
an adhesive coating from a test substrate is called peel 
adhesion. The force required can be influenced by 
molecular weight, type and amount of adhesive added. 
In this test force require for removal of tape is 
measured by applying a single tape to stainless steel 
and then the tape is pulled from the substrate at 
1800angle. 
(9) Water vapour transmission rate(35,36,39): water 
vapour transmission rate is determined by placing 
saturated solution of potassium chloride in a 
desiccators and the whole assembly is kept for three 
days to achieve the humid condition above 80% RH. 
Glass vials of equal diameter taken and to this filled one 
gram of fused calcium chloride. Then patches are fixed 
over the brim of vials with the help of adhesive like 
silicon adhesive grease and the vials accurately 
weighed. These vials are then placed in the desiccators 
maintained at 80% RH. Weight gained due to water 
vapour transmission through the film obtained by 
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weighing these vials every 24 hours for seven days. The 
transmission rate is calculated by using formula- 
                   
     
   
 
W= water transmitted in gram 
L= Thickness of film 
S= Exposed surface area 
 
(10) In Vitro Drug release(36,39,41): The paddle over disc 
apparatus (USP apparatus V) can be employed for 
assessment of release of drug from the prepared patch. 
The patches of definite weight are fixed over a glass 
plate with an adhesive. The glass plate is placed in 
dissolution medium and apparatus is equilibrated at 
32±50C. The paddle is set at a distance of 2.5 cm from 
the glass plate and operated at a speed of 50 rpm. The 
sample is withdrawn at appropriate interval and after 
suitable dilution the absorbance is determine 
spectrophotometrically. 
(11) In- vitro skin permeation studies(27,39,41): in vitro 
permeation studies can be performed by using 
diffusion cell like franz diffusion cell or keshary- chien 
diffusion cell. The receptor compartment is filled with 
dissolution medium phosphate buffer saline pH 7.4 and 
is placed on magnetic stirrer with magnetic needle for 
uniform distribution of medium. The temperature is 
maintained at 32±0.50C by using thermostat. The 
isolated rat skin is sandwiched between donor and 
receiver compartment of diffusion cell with the stratum 
corneum facing towards donor compartment side. A 
sample of definite volume is withdrawn at regular 
interval from the receiver compartment and equal 
volume of phosphate buffer saline is replaced. Sample 
are to be filtered through filtering media and analyzed 
spectrophotometrically or HPLC. 
Conclusion:  
TDDS provide a technology by which drug can be placed at 
the site of action without rupturing the skin By using 
polymer and penetration enhancer the system is able to 
transport the sufficient amount of drug to elicit the 
pharmacological response. This drug delivery overcomes the 
challenges associated with current drug delivery and it 
shows a promising future.  
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